

# A systematic review of hepatitis C virus epidemiology in

Liver International

31, 61-80

DOI: [10.1111/j.1478-3231.2011.02540.x](https://doi.org/10.1111/j.1478-3231.2011.02540.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The global health burden of hepatitis C virus infection. <i>Liver International</i> , 2011, 31, 1-3.	1.9	121
2	Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. <i>Journal of Clinical Laboratory Analysis</i> , 2011, 25, 402-408.	0.9	13
3	How can we reduce the burden of Hepatitis C?. <i>Saudi Journal of Gastroenterology</i> , 2011, 17, 227.	0.5	1
4	Healthcare-associated viral and bacterial infections in dentistry. <i>Journal of Oral Microbiology</i> , 2012, 4, 17659.	1.2	106
5	Psychometric Properties of a Standardized Questionnaire of Knowledge, Attitude, and Practice of Iranian Medical Specialists about Viral Hepatitis. <i>Hepatitis Monthly</i> , 2012, 12, e7650.	0.1	6
6	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19757-19762.	3.3	109
7	SASLT practice guidelines: Management of hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 1.	0.5	8
8	Transfusion transmission of HCV, a long but successful road map to safety. <i>Antiviral Therapy</i> , 2012, 17, 1423-1429.	0.6	28
9	Seroprevalence of HBV and HCV among HIV-infected adults in China according to route of HIV infection: high rate of HBV and HCV exposure. <i>Future Virology</i> , 2012, 7, 1015-1020.	0.9	1
10	Back from the Future: Treating Hepatitis C Virus with Conventional Interferon. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 3-6.	0.4	0
11	A Pharmacological Profile of Ribavirin and Monitoring of its Plasma Concentration in Chronic Hepatitis C Infection. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 42-54.	0.4	19
12	Hepatitis C in Punjabâ€”Peeping into Pandoraâ€™s box!. <i>Indian Journal of Gastroenterology</i> , 2012, 31, 223-225.	0.7	0
13	Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 765-773.	0.7	4
14	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2â€™6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012, 56, 1247-1253.	1.8	98
16	HCV and HIV Infection among Heroin Addicts in Methadone Maintenance Treatment (MMT) and Not in MMT in Changsha and Wuhan, China. <i>PLoS ONE</i> , 2012, 7, e45632.	1.1	10
17	The Interaction among Insulin Resistance, Liver Fibrosis and Early Virological Response in Egyptian Patients with Chronic Hepatitis C. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 325-329.	1.8	15
18	Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. <i>Oncology Letters</i> , 2012, 3, 704-712.	0.8	35
19	Viral infections: A tale of two genomes. <i>NursePrescribing</i> , 2012, 10, 551-555.	0.1	0

#	ARTICLE	IF	CITATIONS
20	Hepatitis C Virus in Arab World: A State of Concern. Scientific World Journal, The, 2012, 2012, 1-12.	0.8	65
21	The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2012, 57, 2213-2221.	1.1	25
22	Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterology, 2012, 12, 32.	0.8	36
23	Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clinical Infectious Diseases, 2012, 55, S10-S15.	2.9	263
24	The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2012, 35, 1209-1220.	1.9	7
25	Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology, 2012, 55, 742-748.	3.6	318
26	Hepatitis C virus infection in the Middle East and North Africa (MENA) region: injecting drug users (IDUs) is an under-investigated population. Infection, 2012, 40, 1-10.	2.3	12
27	Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 553-562.	8.2	833
28	The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infectious Diseases, 2013, 13, 288.	1.3	296
29	Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatology International, 2013, 7, 500-507.	1.9	16
30	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow – Results from a community based survey and laboratory surveillance. Travel Medicine and Infectious Disease, 2013, 11, 301-309.	1.5	11
31	Primary liver cancer incidence and survival in ethnic groups in England, 2001–2007. Cancer Epidemiology, 2013, 37, 34-38.	0.8	6
32	The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations. Transfusion, 2013, 53, 2489-2497.	0.8	10
33	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology, 2013, 58, 655-662.	1.8	225
34	Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. Journal of Infectious Diseases, 2013, 208, 1000-1007.	1.9	27
36	Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study. Hepatology International, 2013, 7, 1040-1049.	1.9	29
37	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. Current Hepatitis Reports, 2013, 12, 261-268.	0.3	0
38	Hepatitis C virus genotype diversity in Shanghai, China. Archives of Virology, 2013, 158, 187-191.	0.9	3

#	ARTICLE	IF	CITATIONS
39	Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. <i>International Journal of Infectious Diseases</i> , 2013, 17, e535-e538.	1.5	25
40	HCV infection prevalence in a population recruited at health centers in Jordan. <i>Journal of Epidemiology and Global Health</i> , 2013, 3, 67.	1.1	9
41	Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 150-156.	0.8	13
43	Discordant hepatitis C serological testing in Australia and the implications for organ transplant programs. <i>Journal of Clinical Virology</i> , 2013, 57, 19-23.	1.6	4
44	Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons. <i>Gastroenterology</i> , 2013, 144, 59-61.e6.	0.6	35
45	Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 497-506.	1.1	22
46	The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. <i>Liver International</i> , 2013, 33, 871-883.	1.9	8
47	Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936.	1.9	105
48	Hepatitis C virus vaccines – Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	1.3	34
49	The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. <i>Nature Reviews Microbiology</i> , 2013, 11, 482-496.	13.6	336
50	Advances in the management of hepatitis C. <i>Internal Medicine Journal</i> , 2013, 43, 1265-1271.	0.5	3
51	The Current Hepatitis C Virus Prevalence in China May Have Resulted Mainly from an Officially Encouraged Plasma Campaign in the 1990s: a Coalescence Inference with Genetic Sequences. <i>Journal of Virology</i> , 2013, 87, 12041-12050.	1.5	19
52	Hepatitis C genotype and associated risks factors of patients at University Kebangsaan Malaysia Medical Centre. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 1142-6.	0.3	13
53	Prevalence and Risk Factors of Hepatitis C Virus Infection in Amol City, North of Iran: A Population-Based Study (2008-2011). <i>Hepatitis Monthly</i> , 2013, 13, e13313.	0.1	26
54	Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5037-5044.	1.4	20
55	Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137.	2.9	99
56	Persisting role of healthcare settings in hepatitis C transmission in Pakistan: cause for concern. <i>Epidemiology and Infection</i> , 2013, 141, 1831-1839.	1.0	7
57	Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA. <i>Journal of Clinical Microbiology</i> , 2013, 51, 238-242.	1.8	36

#	ARTICLE	IF	CITATIONS
58	Response to Letters. <i>Journal of Travel Medicine</i> , 2013, 20, 409-410.	1.4	0
59	Epidemiological distribution and genotype characterization of hepatitis C virus and HIV co-infection in Wuhan, China, where the prevalence of HIV is low. <i>Journal of Medical Virology</i> , 2013, 85, 1712-1723.	2.5	15
60	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	1.9	81
61	Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. <i>Liver International</i> , 2013, 33, 727-738.	1.9	32
62	The Incidence of HBV and HCV Infection in Australian Travelers to Asia: Table 1. <i>Journal of Travel Medicine</i> , 2013, 20, 203-205.	1.4	16
63	High Proportion of Hepatitis C Virus in Community Asian American Patients With Non-Liver-related Complaints. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 367-371.	1.1	14
64	Randomized Study of Asunaprevir plus Pegylated Interferon- $\alpha$ and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44
65	The Efficacy and Safety of Telaprevir-based Regimens for Treating Chronic Hepatitis C Virus Genotype 1 Infection: A Meta-analysis of Randomized Trials. <i>Internal Medicine</i> , 2013, 52, 653-660.	0.3	9
66	Increasing Newly Diagnosed Rate and Changing Risk Factors of HCV in Yanbian Prefecture, a High Endemic Area in China. <i>PLoS ONE</i> , 2014, 9, e86190.	1.1	10
67	Hepatitis C Worldwide and in Brazil: Silent Epidemic? Data on Disease including Incidence, Transmission, Prevention, and Treatment. <i>Scientific World Journal</i> , The, 2014, 2014, 1-10.	0.8	25
68	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633.	1.4	135
69	HCC surveillance results in earlier HCC detection: results from an Indian cohort. <i>SpringerPlus</i> , 2014, 3, 610.	1.2	2
70	Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. <i>BMC Infectious Diseases</i> , 2014, 14, 564.	1.3	31
71	Migration Patterns of Hepatitis C Virus in China Characterized for Five Major Subtypes Based on Samples from 411 Volunteer Blood Donors from 17 Provinces and Municipalities. <i>Journal of Virology</i> , 2014, 88, 7120-7129.	1.5	32
72	A model for southern mediterranean research institute self-assessment: A SWOT analysis-based approach to promote capacity building at Theodor Bilharz Research Institute in Cairo (Egypt). <i>Arab Journal of Gastroenterology</i> , 2014, 15, 92-97.	0.4	1
73	Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas. <i>Seminars in Liver Disease</i> , 2014, 34, 089-097.	1.8	34
74	Interaction of Hepatitis C Viral Proteins with Cellular Oncoproteins in the Induction of Liver Cancer. <i>ISRN Virology</i> , 2014, 2014, 1-11.	0.5	4
75	Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection. <i>Clinical Investigation</i> , 2014, 4, 361-371.	0.0	1

#	ARTICLE	IF	CITATIONS
76	Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology American Society of Hematology Education Program, 2014, 2014, 590-598.	0.9	22
77	Cost and time savings from a rapid access model of care using transient elastography to screen and triage patients with chronic Hepatitis C infection. Journal of Medical Economics, 2014, 17, 159-165.	1.0	5
78	Transfusion transmitted infections in thalassaemics: need for reappraisal of blood screening strategy in India. Transfusion Medicine, 2014, 24, 79-88.	0.5	12
79	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	0.8	97
80	Predicting the Probability of Experiencing Clinically Significant Drug-Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV. AIDS Patient Care and STDs, 2014, 28, 513-516.	1.1	1
81	Distribution and clinical correlates of viral and host genotypes in <scp>C</scp>hinese patients with chronic hepatitis <scp>C</scp> virus infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 545-553.	1.4	113
82	Daclatasvir for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2014, 8, 725-738.	1.4	7
83	Robust and Persistent Replication of the Genotype 6a Hepatitis C Virus Replicon in Cell Culture. Antimicrobial Agents and Chemotherapy, 2014, 58, 2638-2646.	1.4	29
84	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Medical Research Methodology, 2014, 14, 39.	1.4	2
85	Current Challenges and the Management of Chronic Hepatitis C in Mainland China. Journal of Clinical Gastroenterology, 2014, 48, 679-686.	1.1	51
86	Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian Journal of Transfusion Science, 2014, 8, 32.	0.1	6
87	In Vitro Inhibition of Hepatitis C Virus by Antisense Oligonucleotides in PBMC Compared to Hepatoma Cells. BioMed Research International, 2014, 2014, 1-7.	0.9	3
88	Distribution Pattern of Hepatitis C Virus Genotypes and Correlation with Viral Load and Risk Factors in Chronic Positive Patients. Intervirology, 2014, 57, 311-318.	1.2	24
89	Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. Value in Health Regional Issues, 2014, 3, 5-11.	0.5	33
90	Optimizing Outcome of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplantation: Moving Forward by Looking Back. Transplantation Proceedings, 2014, 46, 822-827.	0.3	3
91	Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies. Journal of Virological Methods, 2014, 204, 6-10.	1.0	16
92	Impact of New Hepatitis C Treatments in Different Regions of the World. Gastroenterology, 2014, 146, 1145-1150.e4.	0.6	48
93	Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology, 2014, 59, 395-407.	3.6	63

#	ARTICLE	IF	CITATIONS
94	Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. <i>Current Gastroenterology Reports</i> , 2014, 16, 371.	1.1	17
95	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147.	1.9	74
96	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	1.0	211
97	Hepatitis C beware—the end is nigh. <i>Lancet, The</i> , 2014, 384, 1557-1560.	6.3	19
98	Global epidemiology and genotype distribution of the hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, S45-S57.	1.8	1,560
99	Identification of Indian sub-continent as hotspot for HCV genotype 3a origin by Bayesian evolutionary reconstruction. <i>Infection, Genetics and Evolution</i> , 2014, 28, 87-94.	1.0	14
100	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet, The</i> , 2014, 384, 1597-1605.	6.3	316
101	The genetic diversity and evolutionary history of hepatitis C virus in Vietnam. <i>Virology</i> , 2014, 468-470, 197-206.	1.1	25
102	Neurologic complications of hepatic viruses. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 123, 647-661.	1.0	4
103	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.	13.9	1,065
104	The association between neighborhood residential rehabilitation and injection drug use in Baltimore, Maryland, 2000–2011. <i>Health and Place</i> , 2014, 28, 142-149.	1.5	9
105	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.	0.4	88
106	Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 106-116.	0.4	67
107	Treatment of chronic hepatitis C: What is new?. <i>Apollo Medicine</i> , 2014, 11, 93-102.	0.0	1
108	Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma. <i>Cytokine</i> , 2014, 68, 50-58.	1.4	9
109	A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2014, 19, 491-499.	0.6	31
110	Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1. <i>Antiviral Therapy</i> , 2014, 19, 501-510.	0.6	26
111	Health care-associated hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 17265.	1.4	39

#	ARTICLE	IF	CITATIONS
112	Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations. <i>Antiviral Therapy</i> , 2015, 20, 271-280.	0.6	4
113	The genotype distribution of hepatitis C in southeastern Taiwan: Clinical characteristics, racial difference, and therapeutic response. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 597-602.	0.8	11
115	Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2015, 94, e2132.	0.4	17
116	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 3. <i>Journal of Viral Hepatitis</i> , 2015, 22, 4-20.	1.0	109
117	Estimation of Cancer Burden Attributable to Infection in Asia. <i>Journal of Epidemiology</i> , 2015, 25, 626-638.	1.1	18
118	Seroprevalencia de hepatitis C en usuarios de unidades de medicina familiar en QuerÃ©taro, MÃ©xico. <i>AtenciÃ³n Familiar</i> , 2015, 22, 2-6.	0.0	2
120	Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy. <i>Molecular Medicine Reports</i> , 2015, 11, 427-433.	1.1	0
121	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2016, 21, 195-205.	0.6	18
122	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
123	The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2015, 40, 54-63.	1.5	33
124	HCV Screening Behaviors and Infection Status among Vietnamese Americans. <i>American Journal of Health Behavior</i> , 2015, 39, 640-651.	0.6	3
125	The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 6027.	2.0	2
126	Efficacy and safety of a herbal mixture (Viron&reg; tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 799.	2.0	1
127	Viral hepatitis in Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 785-786.	0.5	13
128	Factors Associated with Hepatitis C Knowledge before and after an Educational Intervention among Vietnamese Americans. <i>Clinical Medicine Insights Gastroenterology</i> , 2015, 8, CGast.S24737.	1.0	8
129	Current and future prophylactic vaccines for hepatitis C virus. <i>Vaccine (Auckland, N Z)</i> , 2015, , 31.	1.7	8
130	Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Hubei, Central China. <i>PLoS ONE</i> , 2015, 10, e0137059.	1.1	20
131	Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143492.	1.1	0

#	ARTICLE	IF	CITATIONS
132	Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?. <i>International Journal of Hepatology</i> , 2015, 2015, 1-9.	0.4	2
133	Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. <i>Annals of Hepatology</i> , 2015, 14, 642-651.	0.6	17
134	Hepatitis C virus, pregnancy and postnatal care. <i>Gastrointestinal Nursing</i> , 2015, 13, 26-32.	0.0	0
135	Hepatocellular carcinoma in Asia: Prevention strategy and planning. <i>World Journal of Hepatology</i> , 2015, 7, 1708.	0.8	91
136	A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice. <i>Journal of Virology</i> , 2015, 89, 7991-8002.	1.5	31
137	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 9-20.	1.4	6
138	Hepatitis C virus infection in the general population: A large community-based study in Mianyang, West China. <i>BioScience Trends</i> , 2015, 9, 97-103.	1.1	10
139	Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 696-706.	1.9	70
140	Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. <i>Virology Journal</i> , 2015, 12, 109.	1.4	36
141	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015, , 101669.	1.6	0
142	Insulin Resistance and Prediabetes in Hepatitis C Virus Patients. <i>American Journal of the Medical Sciences</i> , 2015, 350, 77-80.	0.4	5
143	Evaluation of the Elecsys® Anti-HCV II assay for routine hepatitis C virus screening of different Asian Pacific populations and detection of early infection. <i>Journal of Clinical Virology</i> , 2015, 64, 20-27.	1.6	20
144	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. <i>Journal of Infection</i> , 2015, 70, 197-205.	1.7	35
145	Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. <i>Leukemia Research</i> , 2015, 39, 151-156.	0.4	12
146	Hepatitis C virus infection increases the risk of developing peripheral arterial disease: A 9-year population-based cohort study. <i>Journal of Hepatology</i> , 2015, 62, 519-525.	1.8	60
147	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	1.0	92
148	Rapid detection of HCV genotyping 1a, 1b, 2a, 3a, 3b and 6a in a single reaction using two-melting temperature codes by a real-time PCR-based assay. <i>Journal of Virological Methods</i> , 2015, 222, 85-90.	1.0	13
149	Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 134-141.	0.4	14

#	ARTICLE	IF	CITATIONS
150	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 593-605.	0.6	4
151	A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. <i>Hepatology International</i> , 2015, 9, 378-390.	1.9	82
152	Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 641-648.	0.5	10
153	Changing epidemiology of hepatitis C virus genotypes in the central region of Argentina. <i>Archives of Virology</i> , 2015, 160, 909-915.	0.9	6
154	Acute HCV Infection: Diagnosis, Epidemiology and Current Treatment Options. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 113-126.	0.8	0
155	A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries. <i>PLoS Medicine</i> , 2015, 12, e1001795.	3.9	32
156	Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1995-2004.	1.2	22
157	A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Hepatology</i> , 2015, 62, 1204-1206.	1.8	52
158	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. <i>Hepatology International</i> , 2015, 9, 486-507.	1.9	18
159	How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. <i>Hepatology</i> , 2015, 62, 31-39.	3.6	25
160	Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 2560-2571.	1.1	12
161	Hepatitis C: An Eastern Perspective. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 793-805.	1.0	4
162	IL6 gene allele-specific C/EBPβ-binding activity affects the development of HBV infection through modulation of Th17/Treg balance. <i>Genes and Immunity</i> , 2015, 16, 528-535.	2.2	11
163	Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 761-773.	1.0	14
164	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 515-522.	1.8	114
165	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	1.6	159
166	Serum Soluble CD14 in Egyptian Patients with Chronic Hepatitis C: Its Relationship to Disease Progression and Response to Treatment. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 563-568.	0.5	8
167	The safety of daclatasvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1787-1797.	1.0	3

#	ARTICLE	IF	CITATIONS
168	Epidemiology of Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 699-716.	1.0	30
169	Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 36-45.	4.6	75
170	Hepatitis C virus genotype 3: a genotype that is not "easy-to-treat". <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 375-385.	1.4	15
171	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
172	Novel non-invasive biological predictive index for liver fibrosis in hepatitis C virus genotype 4 patients. <i>World Journal of Hepatology</i> , 2016, 8, 1392.	0.8	2
173	An outbreak of HCV genotype 6a and 2a infection in South China: Confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region. <i>Molecular Medicine Reports</i> , 2016, 14, 4285-4292.	1.1	2
174	How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. <i>BMC Health Services Research</i> , 2016, 16, 247.	0.9	5
175	Epidemiology, Diagnosis and Management of Extra-Pulmonary Tuberculosis in a Low-Prevalence Country: A Four Year Retrospective Study in an Australian Tertiary Infectious Diseases Unit. <i>PLoS ONE</i> , 2016, 11, e0149372.	1.1	29
176	Impact of HCV Infection on Diabetes Patients for the Risk of End-Stage Renal Failure. <i>Medicine (United States)</i> , 2016, 95, e2702.	0.4	21
177	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. <i>Journal of Hepatology</i> , 2016, 65, 879-887.	1.8	29
178	Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. <i>Canadian Journal of Microbiology</i> , 2016, 62, 608-616.	0.8	1
179	Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 643-656.	1.2	11
180	Glutathione S-Transferase M1 and T1 Gene Polymorphisms and the Outcome of Chronic Hepatitis C Virus Infection in Egyptian Patients. <i>Annals of Human Genetics</i> , 2016, 80, 32-37.	0.3	3
181	Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5368-5378.	1.4	72
182	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e2702.	0.4	34
183	Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings. <i>Tropical Medicine and International Health</i> , 2016, 21, 603-609.	1.0	20
184	Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain. <i>Gastroenterology</i> (English Edition), 2016, 39, 656-662.	0.0	1
185	Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. <i>Infectious Agents and Cancer</i> , 2016, 11, 53.	1.2	63

#	ARTICLE	IF	CITATIONS
186	Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses, and <i>Treponema pallidum</i> infections among blood donors at Shiyan, Central China. <i>BMC Infectious Diseases</i> , 2016, 16, 531.	1.3	22
187	Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e3853.	0.4	38
188	Access to needle and syringe programs by people who inject image and performance enhancing drugs. <i>International Journal of Drug Policy</i> , 2016, 31, 199-200.	1.6	22
189	Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. <i>International Journal of Infectious Diseases</i> , 2016, 46, 116-125.	1.5	55
190	Seroprevalencia de hepatitis C en población con factores de riesgo del suroeste de la Comunidad de Madrid. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 656-662.	0.2	3
191	Dysregulation of male sex hormones in chronic hepatitis C patients. <i>Andrologia</i> , 2016, 48, 82-86.	1.0	13
192	Nationwide survey of specialist knowledge on current standard of care (PegIFN/RBV) and barriers of care in chronic hepatitis C patients in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1995-2003.	1.4	9
193	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1860-1867.	1.4	32
194	Potential market size and impact of hepatitis C treatment in low- and middle-income countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 522-534.	1.0	15
195	Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw121.	0.4	12
196	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 36-44.	3.7	61
197	Viral hepatitis: Indian scenario. <i>Medical Journal Armed Forces India</i> , 2016, 72, 204-210.	0.3	37
198	Epidemiology of hepatitis C in Islamic Republic of Iran. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 969-972.	0.5	0
199	Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 469-477.	0.7	10
200	Tackling the Hepatitis C Disease Burden in Punjab, India. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 224-232.	0.4	34
201	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43
202	Utilization and prescription patterns of traditional Chinese medicine for patients with hepatitis C in Taiwan: a population-based study. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 397.	3.7	18
203	Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. <i>World Journal of Gastroenterology</i> , 2016, 22, 7824.	1.4	621

#	ARTICLE	IF	CITATIONS
204	Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?. <i>BMJ Open</i> , 2016, 6, e010661.	0.8	14
205	Management of hepatitis C genotype 4 in the directly acting antivirals era. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000112.	1.1	13
206	Prevalence of hepatitis B and C viruses in HIV-1 positive patients in China: a cross-sectional study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20659.	1.2	39
207	Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. <i>BMJ Open</i> , 2016, 6, e012016.	0.8	12
208	Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. <i>BMC Gastroenterology</i> , 2016, 16, 91.	0.8	8
209	Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1455-1461.	0.8	21
210	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e4243.	0.4	14
211	Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 7.	1.7	3
212	Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India. <i>Hepatology International</i> , 2016, 10, 988-995.	1.9	6
213	Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 273-279.	0.6	3
214	Hepatitis-related stigma in chronic patients: A qualitative study. <i>Applied Nursing Research</i> , 2016, 29, 206-210.	1.0	27
215	CKD and Infectious Diseases in Asia Pacific: Challenges and Opportunities. <i>American Journal of Kidney Diseases</i> , 2016, 68, 148-160.	2.1	35
216	Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 94-107.	1.1	26
217	Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. <i>Clinical Pharmacokinetics</i> , 2016, 55, 605-613.	1.6	44
218	Prevention of infection-related cancers in the WHO Western Pacific Region. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 13-22.	0.6	21
219	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. <i>Journal of Hepatology</i> , 2016, 64, 292-300.	1.8	38
220	Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. <i>Journal of Advanced Research</i> , 2017, 8, 131-137.	4.4	15
221	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	3.7	45

#	ARTICLE	IF	CITATIONS
222	Effects of a mixed media education intervention program on increasing knowledge, attitude, and compliance with standard precautions among nursing students: A randomized controlled trial. <i>American Journal of Infection Control</i> , 2017, 45, 389-395.	1.1	41
223	HCV management in resource-constrained countries. <i>Hepatology International</i> , 2017, 11, 245-254.	1.9	10
224	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	117
225	Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 25.	1.0	19
226	Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	28
227	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. <i>Clinical Infectious Diseases</i> , 2017, 64, 860-869.	2.9	61
228	Economic Burden of Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 579-594.	1.0	54
229	Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. <i>Sexual Health</i> , 2017, 14, 345.	0.4	5
230	Polymorphisms of chemokine receptor genes and clearance of hepatitis C virus infection in Chinese population. <i>Gene</i> , 2017, 624, 1-5.	1.0	5
231	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017, 22, 1075-1083.	1.9	31
232	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2141-2149.	1.1	4
233	Daclatasvir/asunaprevir/beclabuvir, allâ€œoral, fixedâ€œdose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1998-2005.	1.4	15
234	Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. <i>International Journal of Infectious Diseases</i> , 2017, 55, 56-71.	1.5	21
235	Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 151-155.	0.4	2
236	Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. <i>Microbial Pathogenesis</i> , 2017, 112, 320-326.	1.3	17
237	Direct-acting antiviral agents for HCV infection affecting people who inject drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 641-651.	8.2	127
238	The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 731-740.	1.9	21
239	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. <i>International Journal of Drug Policy</i> , 2017, 47, 107-116.	1.6	114

#	ARTICLE	IF	CITATIONS
240	The oncologic burden of hepatitis C virus infection: A clinical perspective. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 411-431.	157.7	88
241	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 348-353.	0.5	4
242	Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. <i>Hospital Pharmacy</i> , 2017, 52, 294-301.	0.4	4
243	Real-world treatment patterns and clinical outcomes of HCV treatment-naïve patients in China: an interim analysis from the CCgenos study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 244-252.	1.4	27
244	Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. <i>Current Medical Research and Opinion</i> , 2017, 33, 1-10.	0.9	40
245	Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. <i>Current Medical Research and Opinion</i> , 2017, 33, 11-21.	0.9	15
246	Seronegative and occult hepatitis C virus infections in patients with hematological disorders. <i>Archives of Virology</i> , 2017, 162, 63-69.	0.9	14
247	Clinical Manifestations of Acute and Chronic Hepatitis. , 2017, , 363-374.e4.		0
248	No suitable precise or optimized epidemiologic search filters were available for bibliographic databases. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 112-118.	2.4	10
249	Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 859-863.	1.4	21
250	Association between visceral obesity and hepatitis C infection stratified by gender: a cross-sectional study in Taiwan. <i>BMJ Open</i> , 2017, 7, e017117.	0.8	5
251	The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine. <i>Frontiers in Microbiology</i> , 2017, 8, 2163.	1.5	16
252	Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. <i>PLoS ONE</i> , 2017, 12, e0167770.	1.1	29
253	Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. <i>Hospital Pharmacy</i> , 2017, 52, 294-301.	0.4	2
254	Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study. <i>Annals of Hepatology</i> , 2017, 16, 893-900.	0.6	14
255	Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. <i>Hepatology Communications</i> , 2018, 2, 595-606.	2.0	19
256	Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. <i>Journal of the International AIDS Society</i> , 2018, 21, e25059.	1.2	21
257	Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. <i>Liver International</i> , 2018, 38, 1552-1561.	1.9	28

#	ARTICLE	IF	CITATIONS
258	Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. <i>Journal of Medical Virology</i> , 2018, 90, 1508-1515.	2.5	8
259	Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. <i>BMC Infectious Diseases</i> , 2018, 18, 42.	1.3	43
260	Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir+Ribavirin for Hepatitis C Virus Genotype 4 Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1341-1347.	1.1	13
261	Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. <i>Journal of Viral Hepatitis</i> , 2018, 25, 945-951.	1.0	18
262	Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 44-52.	0.8	26
263	Utility of diffusion weighted imaging (DWI) in assessment of liver fibrosis. <i>Alexandria Journal of Medicine</i> , 2018, 54, 347-352.	0.4	3
264	Hepatitis C virus infection in Jeddah city, Saudi Arabia: Seroprevalence and knowledge. <i>Journal of Medical Virology</i> , 2018, 90, 526-531.	2.5	5
265	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. <i>Journal of Gastroenterology</i> , 2018, 53, 557-565.	2.3	103
266	Clinical profile of hepatitis C virus infection in a developing country: India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 926-933.	1.4	20
267	Low cost detection of hepatitis C virus RNA in HCV infected patients by SYBR Green I real-time PCR. <i>Alexandria Journal of Medicine</i> , 2018, 54, 481-485.	0.4	4
268	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018, 21, 612-621.	0.1	8
269	Relationship between hepatic progenitor cells and stellate cells in chronic hepatitis C genotype 4. <i>Apmis</i> , 2018, 126, 14-20.	0.9	12
270	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. <i>Journal of Gastroenterology</i> , 2018, 53, 566-575.	2.3	107
271	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	1.4	28
272	High prevalence of syphilis, HBV, and HCV coinfection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital. <i>Journal of Medical Virology</i> , 2018, 90, 101-108.	2.5	23
273	Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2435-2441.	1.1	10
274	The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study. <i>Drug Discoveries and Therapeutics</i> , 2018, 12, 368-373.	0.6	3
275	Trends in Incidence of Two Major Subtypes of Liver and Bile Duct Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030. <i>Journal of Cancer Epidemiology</i> , 2018, 2018, 1-9.	0.5	11

#	ARTICLE	IF	CITATIONS
276	Systematic overview of hepatitis C infection in the Middle East and North Africa. <i>World Journal of Gastroenterology</i> , 2018, 24, 3038-3054.	1.4	30
277	Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland. <i>Journal of Public Health and Epidemiology</i> , 2018, 10, 241-250.	0.1	0
278	Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-6.	0.7	154
279	Effect of a vegetarian diet on the treatment efficacy of peginterferon plus ribavirin in chronic hepatitis C patients: A retrospective cohort study. <i>Advances in Digestive Medicine</i> , 2018, 5, 21-25.	0.1	0
280	Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea. <i>Yonsei Medical Journal</i> , 2018, 59, 1072.	0.9	4
281	Efficacy and tolerability of interferon-free regimen for patients with genotype 1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	0.8	4
282	Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan. <i>Infection, Genetics and Evolution</i> , 2018, 66, 66-71.	1.0	4
283	Public Health and Economic Burden of Hepatitis C Infection in Developing Countries. , 2018, , 25-32.		3
284	Hepatitis C in Developing Countries in Southeast Asia. , 2018, , 97-104.		2
285	Health risk and health seeking behaviours among people who inject performance and image enhancing drugs who access needle syringe programs in Australia. <i>Drug and Alcohol Review</i> , 2018, 37, 837-846.	1.1	35
286	Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. <i>Journal of Infectious Diseases</i> , 2018, 218, 1722-1729.	1.9	202
287	Prevalence of Hepatitis B and C virus infection and their co-relation with hematological and hepatic parameters in subjects undergoing Premarital Screening in the Jazan Region, Kingdom of Saudi Arabia. <i>Pakistan Journal of Medical Sciences</i> , 2018, 34, 316-321.	0.3	14
288	Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2018, 69, 1178-1187.	1.8	98
289	Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt. <i>Journal of Medical Virology</i> , 2018, 90, 1745-1749.	2.5	4
290	Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada. <i>Canadian Liver Journal</i> , 2018, 1, 34-50.	0.3	15
291	Findings from a large Asian chronic hepatitis C real-life study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1533-1542.	1.0	8
292	The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. <i>PLoS ONE</i> , 2018, 13, e0200461.	1.1	27
293	Hepatitis C Virus. , 2018, , 3-11.		0

#	ARTICLE	IF	CITATIONS
294	Hepatitis C in Egypt. , 2018, , 41-56.		4
295	Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 43-52.	0.6	2
296	&lt;p&gt;Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2565-2577.	2.0	20
297	Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. <i>Hepatology Research</i> , 2019, 49, 1441-1450.	1.8	11
298	Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. <i>Scientific Reports</i> , 2019, 9, 10596.	1.6	18
299	Viral hepatitis among acute hepatitis patients attending tertiary care hospital in central India. <i>VirusDisease</i> , 2019, 30, 367-372.	1.0	7
300	Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India. <i>Epidemiology and Infection</i> , 2019, 147, e283.	1.0	8
301	Seroprevalence and trends in transfusion transmissible infections among voluntary non-remunerated blood donors at the Malawi Blood Transfusion Service-a time trend study. <i>Malawi Medical Journal</i> , 2019, 31, 118.	0.2	20
302	Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. <i>PLoS ONE</i> , 2019, 14, e0221769.	1.1	33
303	Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002894.	3.9	8
304	Acute Hepatitis C. , 2019, , 197-217.		0
305	Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. <i>PLoS ONE</i> , 2019, 14, e0217964.	1.1	14
306	Seroprevalence and risk factors associated with HBV and HCV infection among subjects with type 2 diabetes from South India. <i>Diabetes Research and Clinical Practice</i> , 2019, 153, 133-137.	1.1	7
307	Clinical features of Kaposi's sarcoma: experience from a Taiwanese medical center. <i>International Journal of Dermatology</i> , 2019, 58, 1388-1397.	0.5	4
308	Five-year conditional survival for patients with hepatocellular carcinoma in Queensland, Australia. <i>GastroHep</i> , 2019, 1, 61-69.	0.3	0
309	Hepatitis B Virus, Hepatitis C Virus, the Microbiome, and Hepatocellular Carcinoma. , 2019, , 41-54.		0
310	Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. <i>Journal of Medical Virology</i> , 2019, 91, 1313-1318.	2.5	12
311	Acute Hepatitis C. , 2019, , 45-65.		0

#	ARTICLE	IF	CITATIONS
312	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. <i>Journal of Infection and Public Health</i> , 2019, 12, 502-508.	1.9	1
313	Biliary Tract and Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 519-538.	0.6	5
314	Diversity of hepatitis C virus infection among HIV-infected people who inject drugs in India. <i>VirusDisease</i> , 2019, 30, 490-497.	1.0	3
315	Seroprevalence of Anti-HIV-1, Anti-HIV-2, Hepatitis B Surface Antigen, and Anti-HCV in Eye Donors in a Tertiary Eye Hospital, Chennai, India, in the Past 13 years (2005â€“2017). <i>Cornea</i> , 2019, 38, 737-741.	0.9	3
316	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 186-190.	0.6	3
317	Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 595-598.	0.6	1
318	Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study. <i>BMC Nephrology</i> , 2019, 20, 417.	0.8	15
319	Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 40-48.	1.4	39
320	Clinical Epidemiology of Hepatitis C Virus. , 2019, , 149-170.		1
321	The Efficacy of Argon Plasma Coagulation versus Carvedilol for Treatment of Portal Hypertensive Gastropathy. <i>Digestion</i> , 2020, 101, 651-658.	1.2	4
322	Circulating Resistin Is Associated with Plasma Glucagon-Like Peptide-1 in Cirrhotic Patients with Hepatitis C Virus Genotype-4 Infection. <i>Endocrine Research</i> , 2020, 45, 17-23.	0.6	4
323	Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCVâ€“infected Japanese Subjects in Phase 3 CERTAINâ€“1 and CERTAINâ€“2 Trials. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 331-339.	1.0	4
324	Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups. <i>Journal of Clinical Epidemiology</i> , 2020, 119, 26-35.	2.4	0
325	Advantage of liver stiffness measurement before and after directâ€“acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. <i>Hepatology Research</i> , 2020, 50, 426-438.	1.8	13
326	Micro-elimination of Chronic Hepatitis C by Universal Screening plus Direct Acting Antivirals for Incarcerated Persons in Taiwan. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa301.	0.4	27
327	Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. <i>Liver Research</i> , 2020, 4, 153-158.	0.5	1
328	A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C. <i>BMC Infectious Diseases</i> , 2020, 20, 802.	1.3	3
329	Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. <i>Frontiers in Pharmacology</i> , 2020, 11, 550205.	1.6	11

#	ARTICLE	IF	CITATIONS
330	Diverse HCV Strains And HIV URFS Identified Amongst People Who Inject Drugs In India. Scientific Reports, 2020, 10, 7214.	1.6	4
331	Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS ONE, 2020, 15, e0233446.	1.1	4
332	Molecular epidemiology and genotype distribution of hepatitis C in Pakistan; a multicenter cross-sectional study. Infection, Genetics and Evolution, 2020, 84, 104372.	1.0	5
333	Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC Gastroenterology, 2020, 20, 47.	0.8	24
334	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	1.6	7
335	Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. Journal of Viral Hepatitis, 2020, 27, 505-513.	1.0	2
336	<p>A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants</p>. Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 1-11.	0.8	3
337	HCV NS3 serine protease as a drug target for the development of drugs against hepatocellular carcinoma (liver cancer). , 2020, , 243-263.		2
338	Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines, 2020, 8, 53.	2.1	5
339	Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease. Blood Purification, 2020, 49, 692-699.	0.9	2
340	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 39-56.	3.7	68
341	Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum. Journal of Biological Chemistry, 2021, 296, 100018.	1.6	3
342	The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS ONE, 2021, 16, e0246376.	1.1	1
343	Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. , 2021, , 259-297.		0
344	Patients With Chronic Hepatitis C Virus Infection Are at an Increased Risk of Colorectal Cancer: A Nationwide Population-Based Case-Control Study in Taiwan. Frontiers in Oncology, 2020, 10, 561420.	1.3	8
345	Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India. BMJ Open, 2021, 11, e042280.	0.8	5
346	Increased Risk of Age-Related Macular Degeneration with Chronic Hepatitis C Virus Infection: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan. Viruses, 2021, 13, 790.	1.5	5
347	Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0251673.	1.1	11

#	ARTICLE	IF	CITATIONS
348	Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. <i>Current Medical Science</i> , 2021, 41, 581-586.	0.7	2
349	Relation between the severity of liver cirrhosis and neurological symptoms, nerve conduction study results, and motor unit number estimation. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1312-1318.	1.0	1
350	The association of Fat Mass and Obesity-Associated (FTO) gene polymorphism (rs9939609) with metabolic disturbances and response to sofosbuvir, ribavirin and interferon triple therapy in patients with viral hepatitis C. <i>Meta Gene</i> , 2021, 28, 100888.	0.3	0
351	Solubility Behavior of Boc-L-proline in 14 Pure Solvents from 283.15 to 323.15 K. <i>Journal of Chemical &amp; Engineering Data</i> , 2021, 66, 2812-2821.	1.0	7
352	A systematic review of outbreaks of bloodborne infections (hepatitis B and C, HIV) transmitted from patient to patient in healthcare settings. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2021, 98, 319-330.	0.3	2
353	Phylogenetic analysis of the 5' untranslated region of HCV from cirrhotic patients in Khyber Pakhtunkhwa, Pakistan. <i>Scientific Reports</i> , 2021, 11, 15023.	1.6	1
354	Public Health Surveillance Systems in the Eastern Mediterranean Region: Bibliometric Analysis of Scientific Literature. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e32639.	1.2	6
356	Evaluation of long-term changes of aspartate-platelet ratio index, FIB4, and liver stiffness in chronic hepatitis C patients successfully treated by direct-acting antivirals. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	1
357	Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. <i>Microbial Biotechnology</i> , 2021, 14, 2199-2213.	2.0	7
358	Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 942-953.	0.1	1
359	Seroprevalence of hepatitis B and C viral infections in the premarital adult population of Al Majmaah, Saudi Arabia. <i>Malawi Medical Journal</i> , 2021, 33, 221-225.	0.2	0
360	Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 167.	0.3	3
361	Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmaco-economic study in hepatitis C patients. <i>Perspectives in Clinical Research</i> , 2021, 12, 76.	0.5	0
362	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. <i>Hepatology</i> , 2018, 67, 505-513.	3.6	94
363	Circulation of an atypical hepatitis C virus (HCV) strain at a dialysis unit in northeast India. <i>MicrobiologyOpen</i> , 2021, 10, e1147.	1.2	3
364	Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. <i>Antiviral Research</i> , 2017, 137, 112-124.	1.9	8
365	Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. <i>International Journal of Drug Policy</i> , 2017, 47, 69-76.	1.6	6
366	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. <i>Liver International</i> , 2020, 40, 2385-2393.	1.9	5

#	ARTICLE	IF	CITATIONS
367	Epidemiology of viral hepatitis B and C in Punjab, Pakistan: a multicenter cross-sectional study, 2017-18. F1000Research, 0, 8, 2065.	0.8	7
368	Study of the Role of Insulin Resistance as a Risk Factor in Hcv Related Hepatocellular Carcinoma. Journal of the Egyptian Society of Parasitology, 2015, 45, 107-113.	0.1	3
369	Analysis of IL28B Variants in an Egyptian Population Defines the 20 Kilobases Minimal Region Involved in Spontaneous Clearance of Hepatitis C Virus. PLoS ONE, 2012, 7, e38578.	1.1	31
370	Hepatitis C Virus in Vietnam: High Prevalence of Infection in Dialysis and Multi-Transfused Patients Involving Diverse and Novel Virus Variants. PLoS ONE, 2012, 7, e41266.	1.1	50
371	Survival in Liver Transplant Recipients with Hepatitis B- or Hepatitis C-Associated Hepatocellular Carcinoma: The Chinese Experience from 1999 to 2010. PLoS ONE, 2013, 8, e61620.	1.1	15
372	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0141715.	1.1	74
373	Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. PLoS ONE, 2016, 11, e0147879.	1.1	19
374	Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection. PLoS ONE, 2018, 13, e0191799.	1.1	6
375	Benefits of Curing Hepatitis C Infection. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 85-90.	0.5	15
376	Evaluation of some available HCV antibody detection tests (ELISA, Chemiluminescence, Immune Assay) and RT-PCR assay in the diagnosis of Hepatitis C virus infection. The Egyptian Journal of Hospital Medicine, 2018, 72, 4874-4879.	0.0	7
377	Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Na <sup>+</sup> ve Difficult to Treat HCV Patients. Infectious Disorders - Drug Targets, 2020, 20, 43-48.	0.4	4
378	Hepatitis C in the Eastern Mediterranean Region. Eastern Mediterranean Health Journal, 2013, 19, 587-588.	0.3	26
379	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clinical and Molecular Hepatology, 2013, 19, 60.	4.5	8
380	Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012. Clinical and Molecular Hepatology, 2015, 21, 249.	4.5	14
381	Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: An Egyptian study. World Journal of Gastroenterology, 2013, 19, 7711.	1.4	6
382	Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 12722.	1.4	24
383	Interferon- $\gamma$ -related genes and therapeutic response in Chinese hepatitis C patients. World Journal of Gastroenterology, 2015, 21, 4006.	1.4	2
384	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2763.	1.4	6

#	ARTICLE	IF	CITATIONS
385	Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. <i>World Journal of Gastroenterology</i> , 2018, 24, 1361-1372.	1.4	6
386	A 2015 roadmap for the management of hepatitis C virus infections in Asia. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 423.	0.7	19
387	Interferon-Induced Depression in Chronic Hepatitis C. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1128-1138.	1.1	264
388	The spectrum of cutaneous infection in diabetic patients with hepatitis C virus infection: A single-center study from Egypt. <i>Indian Journal of Dermatology</i> , 2014, 59, 247.	0.1	2
389	Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fibrosis in chronic hepatitis C patients. <i>The Egyptian Journal of Internal Medicine</i> , 2016, 28, 140-148.	0.3	3
390	Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection – A brief review of literature. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 531.	0.3	9
391	Hepatitis C virus and other risk factors in hepatocellular carcinoma. <i>Acta Virologica</i> , 2012, 56, 235-240.	0.3	17
392	Effect of Combination of Some Natural Products and Chloroquine on HCV Infection in Egyptian Patients: Pilot Study. <i>Journal of Liver</i> , 2013, 02, .	0.3	4
393	Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. <i>World Journal of Hepatology</i> , 2013, 5, 393.	0.8	22
394	Hepatitis C genotype 6: A concise review and response-guided therapy proposal. <i>World Journal of Hepatology</i> , 2013, 5, 496.	0.8	26
395	Distribution of HCV Genotypes in Patients of with Chronic Hepatitis C in the Eastern Anatolia Region. <i>Viral Hepatitis Journal</i> , 2014, 20, 91-94.	0.1	4
396	Risk factors for higher anti-HCV positivity in a border city in southern Turkey with unique population characteristics. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 574-579.	0.4	10
397	Emerging Therapies for Hepatitis C. <i>Gut and Liver</i> , 2014, 8, 471-479.	1.4	34
398	Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with a High Prevalence of HCV in the Republic of Korea in 2013. <i>Gut and Liver</i> , 2016, 10, 126.	1.4	16
399	The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin. <i>Hepatitis Monthly</i> , 2014, 14, e18793.	0.1	8
400	Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. <i>Hepatitis Monthly</i> , 2016, 16, e37234.	0.1	44
401	Changing Pattern of Clinical Epidemiology on Hepatitis C Virus Infection in Southwest China. <i>Hepatitis Monthly</i> , 2012, 12, 196-204.	0.1	28
402	Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. <i>Hepatitis Monthly</i> , 2012, 12, 196-204.	0.1	27

#	ARTICLE	IF	CITATIONS
403	Seroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Iranian Red Crescent Medical Journal, 2017, 19, .	0.5	2
404	The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya. Virology Discovery, 2013, 1, 3.	0.5	5
405	Diagnostic Accuracy of Multidetector Computed Tomography in Detection of Esophageal Varices. Cureus, 2019, 11, e3933.	0.2	5
406	Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2014, 35, 96-102.	0.0	6
407	Prevalence of HCV Antibodies and HBV Surface Antigen among Workers of Zagazig Faculty of Medicine and its Hospitals. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2013, 3, 65-72.	0.1	0
408	Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. European Journal of Basic Medical Sciences, 2013, 3, 78-82.	0.2	2
409	Assessment of Epstein-Barr (EBV) Virus Infection in Relation to the Response of Chronic Hepatitis C Virus Infected Patients to Interferon-Based Therapy. Suez Canal University Medical Journal, 2015, 18, 125-135.	0.0	0
410	Jeevan Rekha: Counter for Hepatitis C in Haryana. Advanced Research in Gastroenterology & Hepatology, 2016, 1, .	0.1	0
411	How to Prevent Hepatitis B in Pakistan: Role of Social Marketing. Journal of Infectious Diseases and Diagnosis, 2016, 01, .	0.1	0
412	The Frequency of Infectious Diseases in Manzhouli Port from 2012 to 2014. Advances in Infectious Diseases, 2016, 06, 1-6.	0.0	1
413	Treatment Response of Chronic Hepatitis C Patients and Health-Related Quality of Life. Journal of High Institute of Public Health, 2016, 46, 15-24.	0.1	1
414	Post-Splenectomy Portal Venous Thrombosis in Cirrhotic Patients: An Observational Clinical Trial. Journal of Surgery (New York, N Y), 2017, 5, 105.	0.1	0
415	Nutritional status and liver steatosis after direct-acting antiviral treatment for chronic hepatitis C virus infection. Journal of Translational Science, 2017, 3, .	0.2	1
416	Posttransplant De Novo Hepatitis C Virus Infection in Renal Transplant Recipients: Its Impact on Morbidity and Mortality. Experimental and Clinical Transplantation, 2017, 15, 56-60.	0.2	1
417	Determination of hepatitis C virus genotype distribution in AdÄ±yaman province. OrtadoÄŸu TÄ±p Dergisi, 2017, 9, 1-5.	0.1	0
418	Distribution of HCV Genotypes and RNA Viral Load Along with Hemato-Biochemical Analysis of HCV Patients in Rahim Yar Khan, Okara and Toba Tek Singh Districts of Punjab, Pakistan. Hepatitis Monthly, 2017, 17, .	0.1	1
419	The Process of Social Interactions in Patients With Hepatitis B Infection: A Grounded Theory Study. Journal of Client-centered Nursing Care, 0, , 231-237.	0.1	3
420	A longitudinal study of psychiatric consequences of hepatitis C virus patients receiving interferon therapy. Middle East Current Psychiatry, 2017, 24, 145-155.	0.5	0

#	ARTICLE	IF	CITATIONS
421	Assessment of hepatitis C risk factors in center of Iran: A case-control study. <i>Journal of Research in Medical Sciences</i> , 2018, 23, 87.	0.4	7
422	The Curative HCV Treatments in China. <i>Journal of Biosciences and Medicines</i> , 2018, 06, 42-59.	0.1	0
423	Changes in Quality of Life of Chronic Hepatitis C Patients Participating in Clinical Trial. <i>Journal of Fisheries and Marine Sciences Education</i> , 2018, 30, 1725-1735.	0.0	0
425	The Predominance of Genotype 3 in Hepatitis C Virus in the Province of Kahramanmaras, Turkey/Genotype Distribution of Syrian Refugee Patients with Hepatitis C in Kahramanmaras Province. <i>Jundishapur Journal of Microbiology</i> , 2019, In Press, .	0.2	0
426	The Negative Effect of Epstein-Barr Virus on the Response of Hepatitis C Virus Patients to Interferon-ribavirin Therapy. <i>Journal of Pure and Applied Microbiology</i> , 2019, 13, 1191-1198.	0.3	1
427	High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use. <i>Western Pacific Surveillance and Response Journal: WPSAR</i> , 2019, 10, 9-18.	0.3	6
428	The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. <i>Egyptian Rheumatology and Rehabilitation</i> , 2020, 47, .	0.2	2
429	Diagnosis and Management of Hepatitis B and Hepatitis C Infections in Children. <i>Pediatric Infectious Disease</i> , 2020, 2, 12-18.	0.0	0
430	Risk Factors for the Co-infection with HIV, Hepatitis B and C Virus in Syphilis Patients. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00296.	0.6	4
431	Correlation between Serum Ferritin Levels and Liver Stiffness measured by Fibroscan in patients with Chronic Hepatitis C. <i>Pakistan Journal of Medical Sciences</i> , 2020, 36, 355-359.	0.3	2
432	Drug use-results survey of ombitasvir/paritaprevir/ritonavir coformulated tablet in patients with genotype 1 chronic hepatitis C with or without compensated cirrhosis. <i>Acta Hepatologica Japonica</i> , 2021, 62, 690-702.	0.0	1
433	Boceprevir: A new hope against hepatitis C virus. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 213-5.	0.2	1
434	Surveillance system for hepatitis C infection: A practical approach. <i>International Journal of Preventive Medicine</i> , 2012, 3, S48-57.	0.2	2
435	This is hepatitis-it is closer than you think. <i>Indian Journal of Medical Research</i> , 2012, 136, 3-6.	0.4	39
436	Prevalence of hepatitis C virus genotypes in mashhad, northeast iran. <i>Iranian Journal of Public Health</i> , 2012, 41, 56-61.	0.3	14
437	Impact of anthropometrical parameters on portal vein diameter and liver size in a subset of Karachi based population. <i>Pakistan Journal of Medical Sciences</i> , 2014, 30, 384-8.	0.3	1
438	Epidemiological features of hepatitis B and C infection in a high risk population: results of screening programs. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 136-40.	0.6	4
440	Estimating the true prevalence of hepatitis C in rhode island. <i>Rhode Island Medical Journal</i> (2013), 2014, 97, 19-24.	0.2	4

#	ARTICLE	IF	CITATIONS
441	Epidemiological Aspects of Hepatitis B and C Markers in Blood Donors in Kazakhstan; 2000-2011. Iranian Journal of Public Health, 2014, 43, 156-61.	0.3	3
442	Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China. International Journal of Clinical and Experimental Medicine, 2015, 8, 14871-84.	1.3	0
443	Seroprevalence, risk associations, and cost analysis of screening for viral infections among patients of cataract surgery. Indian Journal of Ophthalmology, 2018, 66, 394-399.	0.5	8
444	Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India. Liver International, 2021, , .	1.9	4
445	Illness perception about hepatitis C virus infection: a cross-sectional study from Khyber Pakhtunkhwa Pakistan. BMC Infectious Diseases, 2022, 22, 74.	1.3	6
446	Seroprevalence, risk associations, and cost analysis of screening for viral infections among patients of cataract surgery. Indian Journal of Ophthalmology, 2018, 66, 394.	0.5	16
447	Retrospective multicentre study on the effectiveness of firstâ€line directâ€acting antivirals against hepatitis C virus genotypeâ€1. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 940-947.	0.7	2
448	Knowledge and experience of using performance and image enhancing drugs among attendees of a Needle and Syringe Program in Australia: A qualitative study. Performance Enhancement and Health, 2022, , 100222.	0.8	1
449	Determining the lower limit of detection required for HCV viral load assay for test of cure following directâ€acting antiviralâ€based treatment regimens: Evidence from a global data set. Journal of Viral Hepatitis, 2022, 29, 474-486.	1.0	3
450	Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan. Medicina (Lithuania), 2022, 58, 521.	0.8	2
463	Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. BioMed Research International, 2022, 2022, 1-10.	0.9	3
465	Prevalence of Transfusion-Transmitted Infections (HCV, HIV, Syphilis and Malaria) in Blood Donors: A Large-Scale Cross-Sectional Study. Pathogens, 2022, 11, 726.	1.2	4
466	Hepatitis C virus transmission cluster among injection drug users in Pakistan. PLoS ONE, 2022, 17, e0270910.	1.1	1
467	Distribution of HCV genotypes and HCV RNA viral load in hepatitis infected patients of Kolar region, Karnataka, India. Bioinformation, 2022, 18, 387-391.	0.2	1
468	Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data. Healthcare (Switzerland), 2022, 10, 1400.	1.0	1
469	Correlation Between Fibrosis-4 (FIB-4) Score and Metavir Score of Chronic Hepatitis C (CHC) Patients in Saiful Anwar Hospital Malang. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2020, 20, 23-26.	0.0	0
470	Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a caseâ€control study. BMC Gastroenterology, 2022, 22, .	0.8	0
471	Selective Depletion of ZAP-Binding CpG Motifs in HCV Evolution. Pathogens, 2023, 12, 43.	1.2	1

#	ARTICLE	IF	CITATIONS
472	Conquering C “ Going Beyond Cure. European Medical Journal Hepatology, 0, , 42-51.	1.0	0
473	Communicable Diseases Prevalence among Refugees and Asylum Seekers: Systematic Review and Meta-Analysis. Infectious Disease Reports, 2023, 15, 188-203.	1.5	4
474	Frequency of Hepatitis B and C and its Risk Factors in Pregnant Women Presenting at Jinnah Postgraduate Medical Center, Karachi. , 0, , 83-87.		0